Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source
Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins
BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, today announced the close of a $65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company ("Lilly"), as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners.
The funding will advance Gate's lead molecular gate programs into the clinic and support the continued expansion of its differentiated molecular gate programs across inflammation and other therapeutic areas.
In connection with the financing, Vanessa Carle, Ph.D., Principal at Forbion, will join Gate's Board of Directors, contributing extensive experience in building and scaling innovative therapeutics companies across Europe and the United States.
"Gate represents a rare opportunity to invest in a truly differentiated therapeutic modality with significant advantages over existing treatments," said Dr. Carle. "The Company's molecular gate platform addresses high-value, clinically validated targets across multiple therapeutic areas with an oral small molecule approach, which is something that has eluded the ...
